BACKGROUND In 2023, nirsevimab, a monoclonal antibody against respiratory syncytial virus (RSV), was approved in the United States to be given to infants to prevent bronchiolitis, a leading cause of pediatric hospitalizations. We sought to better understand how parents of otherwise healthy newborns would respond to this recommendation. METHODS We conducted semistructured interviews of purposefully sampled parents of newborns admitted to the well newborn unit between November 2023 and February 2024. Interviews were performed in a constant comparative manner until thematic sufficiency was reached using the Health Beliefs Model as a conceptual framework. RESULTS We conducted 28 interviews: 38% of participants planned to give nirsevimab to their newborn, 25% did not plan to, and 38% were unsure. Four major themes emerged: (1) Major knowledge gaps existed about RSV prophylaxis; (2) trust in pediatrician's recommendation and fear of RSV infection contributed to uptake; (3) parents deferring RSV prophylaxis were concerned about side effects, wanted more time to decide, felt the maternal RSV vaccine was sufficient, and trusted their own prevention measures; and (4) there was misinformation about nirsevimab among parents including a perception that nirsevimab is a new understudied vaccine with similarities to the COVID-19 vaccine. Application of the Health Beliefs Model highlighted actionable opportunities to positively influence decision making around perceived susceptibility and RSV disease severity, benefits, barriers, self-efficacy, and cues to action. CONCLUSIONS Increasing overall awareness of both nirsevimab and RSV in infants, starting conversations during pregnancy to combat misinformation, leveraging trusting relationships with pediatricians and prenatal clinicians can help with future uptake.

中文翻译：

---

父母对新生儿 Nirsevimab 的看法。


背景 2023 年，针对呼吸道合胞病毒 （RSV） 的单克隆抗体 nirsevimab 在美国被批准用于婴儿，以预防毛细支气管炎，这是儿科住院的主要原因。我们试图更好地了解其他方面健康的新生儿的父母会如何回应这一建议。方法 我们对 2023 年 11 月至 2024 年 2 月期间入住健康新生儿病房的有目的地抽样的新生儿父母进行了半结构化访谈。访谈以恒定的比较方式进行，直到使用健康信念模型作为概念框架达到主题充分性。结果我们进行了 28 次访谈：38% 的参与者计划给新生儿服用 nirsevimab，25% 不打算，38% 不确定。出现了四个主要主题： （1） 关于 RSV 预防存在重大知识空白;（2） 对儿科医生建议的信任和对 RSV 感染的恐惧有助于接受;（3） 推迟 RSV 预防的父母担心副作用，希望有更多时间来决定，认为母体 RSV 疫苗就足够了，并相信自己的预防措施;（4） 家长中存在关于 nirsevimab 的错误信息，包括认为 nirsevimab 是一种新的研究不足的疫苗，与 COVID-19 疫苗有相似之处。健康信念模型的应用强调了可操作的机会，可以积极影响围绕感知易感性和 RSV 疾病严重程度、益处、障碍、自我效能和行动线索的决策。 结论提高婴儿对 nirsevimab 和 RSV 的整体认识，在怀孕期间开始对话以打击错误信息，利用与儿科医生和产前临床医生的信任关系有助于未来的吸收。